Latest news with #VertexPharmaceuticalsIncorporated
Yahoo
15-07-2025
- Business
- Yahoo
EU Commission Approves Vertex Pharmaceutical's (VRTX) Cystic Fibrosis Treatment
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs' top healthcare stock picks. On July 1, the European Commission approved the company's new cystic fibrosis treatment, ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor) for treating cystic fibrosis. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. The approval comes on the basis of ALYFTREK demonstrating non-inferiority compared to the existing treatment, KAFTRIO, in terms of lung function measurement. 'Deutivacaftor/tezacaftor/vanzacaftor has shown it can deliver greater reductions in sweat chloride compared to standard of care,' said Professor Marcus A. Mall of Charité Universitätsmedizin Berlin, according to the press release statement. With the approval, Vertex Pharmaceuticals stands to target over 31,000 people struggling with cystic fibrosis across the European Union. It will represent the broadest label for the medicine expected to strengthen the revenue base. The company has delivered a 9% revenue growth over the past 12 months. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company that discovers, develops, and manufactures transformative medicines for people with serious diseases. It focuses on areas of cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain while exploring treatments for type 1 diabetes and kidney disease. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Green Energy Penny Stocks to Buy Right Now and 10 Most Popular AI Penny Stocks to Buy According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-07-2025
- Business
- Yahoo
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
BOSTON, July 08, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. (VRTX-WEB) View source version on Contacts Vertex Pharmaceuticals Incorporated Investor Relations: investorinfo@ Sign in to access your portfolio
Business Wire
08-07-2025
- Business
- Business Wire
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the 'Vertex Pharmaceuticals Second Quarter 2025 Earnings Call.' The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. (VRTX-WEB)
Yahoo
08-07-2025
- Business
- Yahoo
Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)?
PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 1500 Health Care Index returned 5.5% in the first quarter, outperforming the S&P 500's -4.3% return. Biotechnology and healthcare providers and services surpassed the Index in performance during this quarter. Pharmaceuticals, healthcare technology, and medtech also saw gains but lagged the Index. Conversely, life sciences tools and services declined over the same period. During the quarter, the Fund experienced a loss in value, underperforming the Index. Stock selection in biotechnology was the primary cause of the fund's relative underperformance. Stock selection in pharmaceuticals was another area of relative weakness. Whereas stock selection in health care providers, biotechnology, and underweight to life sciences tools & services contributed to better relative results. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first quarter 2025 investor letter, PGIM Jennison Health Sciences Fund highlighted stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company focusing on developing and commercializing therapies for treating cystic fibrosis (CF). The one-month return of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was 1.75%, and its shares lost 5.47% of their value over the last 52 weeks. On July 7, 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stock closed at $459.41 per share, with a market capitalization of $117.975 billion. PGIM Jennison Health Sciences Fund stated the following regarding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in its first quarter 2025 investor letter: "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a commercial stage biopharmaceutical with a core franchise of small molecule cystic fibrosis transmembrane conductance regulator (CFTR) modulators for cystic fibrosis (CF), a genetic and progressively fatal respiratory disease. VRTX has built a unique and unrivaled market position as the dominant market leader in CF, having created and expanded the market into a nearly $10B franchise and growing with the approval of their next-gen CF triple therapy, Alyftrek, which we believe will drive top-line growth and margin expansion in 2025 onwards. VRTX is also developing an acute and chronic pain franchise. VRTX received approval in acute pain expect this launch to begin to contribute in 2H 2025. Pain as a potentially mega blockbuster category is increasingly becoming evident following a 6/7 hit rate for VX-548 in clinical trials (as well as previous-gen asset VX-150 going 2/2 itself). While market development will need to be done, which is true for any new class of drugs, and expectations for acute pain are appropriately measured despite positive feedback, creating a good setup for the early quarters of launch. Beyond CF and pain, VRTX has focused its pipeline around genetically driven diseases with the potential for a transformative clinical benefit. It currently spans 5 disease verticals: sickle cell/beta thalassemia, type 1 diabetes, apolipoprotein L1 (APOL-1) kidney disease, IgA nephropathy (from the recent acquisition of Alpine Immune Sciences), and alpha-1 antitrypsin disease. VRTX has had another strong start to the year and has delivered positively on several clinical trial readouts, as well as beat Q4 revenue estimates and maintained 2025 guidance." A pharmacist delivering a specific medication to a patient in a specialty pharmacy. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 60 hedge fund portfolios held Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) at the end of the first quarter, compared to 68 in the previous quarter. While we acknowledge the potential of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and shared the list of best fundamental stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
25-06-2025
- Business
- Yahoo
Vertex Pharmaceuticals Presents 'Unprecedented' Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880). Zimislecel is an investigational stem cell-derived, fully differentiated islet cell therapy for individuals with type 1 diabetes (T1D) who experience impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were presented at the American Diabetes Association/ADA annual conference in Chicago, specifically during the symposium 'Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy' and were simultaneously published online by the New England Journal of Medicine. The presented data included 12 patients who received a full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. The results consistently demonstrated the transformative potential of zimislecel, showing durable patient benefit with longer follow-up. All 12 participants exhibited engraftment with glucose-responsive endogenous C-peptide production, which remained durable throughout one year of follow-up. Zimislecel was generally well-tolerated, with most adverse events being mild or moderate. Type 1 diabetes (T1D) is an autoimmune disease where the body's insulin-producing beta cells in pancreatic islets are destroyed, leading to insulin deficiency and hyperglycemia. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company that develops and commercializes therapies for treating cystic fibrosis/CF. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
